Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards

Life Health > Life Insurance

Consumers, Insurers and Genetic Information

Your article was successfully shared with the contacts you provided.

This March, 23andMe, a direct-to-consumer (DTC) genetic testing company, received approval from the Food and Drug Administration (FDA) to test for predispositions to breast and ovarian cancer.

While this latest approved test is quite limited, because it only tests for three changes out of the thousands possible in the BRCA1/2 genes, it highlights the growing ability of individuals, and potentially insurers, to gather information about future risk for disease.

Consumers, by and large, perceive increased access to such testing as positive, but insurance experts have predicted that it could send the industry into a death spiral.

Essentially, the argument is that unless insurers have equal access to the results, consumers with a known predisposition to a costly disease would buy excessive amounts of insurance without insurers having the ability to accurately underwrite the coverage.

Consumers, on the other hand, fear that insurers will decline coverage or increase rates in anticipation of a diagnosis, even when only predisposition is indicated and not the actual disease.

(Related: Busy Health Insurance Legal Sector Could Get Busier)

With all of this information in hand, consumers and insurers must work together to establish some guidelines for regulating insurer use of genetic information. Ideally, these guidelines could strike a balance that would give consumers some assurance that insurer access to genetic information would not lead to discrimination, and, at the same time, ensure that insurers have the information needed to effectively underwrite coverage.

The Stakes

Before diving into this debate, one might ask: “Should we even care about insurer use of genetic information?”

For almost a decade now, health insurers have been prohibited, under the Genetic Information Non-discrimination Act (GINA), from collecting genetic information or using that information when underwriting coverage. However, GINA does not apply to long-term care insurance (LTCI) or life insurance products. While fewer Americans have LTCI or life insurance than health insurance, the number of Americans who own such policies is still significant. For instance, the National Association of Insurance Commissioners (NAIC) reports that about 7.2 million Americans own LTC policies. LIMRA)reports that 44% of U.S. households own individual life insurance policies. Thus, insurer use of genetic information has the potential to impact millions of Americans.

Given that insurer use of genetic information might have a far-reaching impact, the next question is: “How should insurer use of genetic information be regulated?”

The Extremes

One option insurers might favor is maintaining the status quo. Currently, at the federal level, LTCI and life insurance companies are allowed to internally set the guidelines for use of customers’ genetic information. Standard practice is that customers are not asked for genetic information, likely because the vast majority of genetic information is not useful when it comes to underwriting coverage.

As medicine and technology advance, however, so will the predictive value of such information, and, therein lies the problem. Insurers may soon be hard pressed not to use any and all genetic information that might provide a leg up on the competition as it relates to underwriting coverage. While this may not seem problematic in purely economic terms, indiscriminate use of such information may increase consumer distrust and prevent some consumers from undergoing valuable genetic testing. Thus, maintaining the status quo is not a viable option.

The option consumers seem to favor is to simply ban insurers from using genetic information, much like is done with race, and, in some contexts, gender. Consumers favor this option for a couple of reasons. First, genetic testing can potentially reveal deeply personal information about an individual’s health, such as a genetic predisposition to an incurable disease, and consumers are, understandably, hesitant to share that information with others. Second, history is rife with examples of misuse of genetic information (e.g., forced sterilization of the mentally deficient in the 1960s), and individuals are, understandably, fearful that genetic information may be used to discriminate against specific individuals or groups again in a similar manner.

A number of European countries have already prohibited insurer use of genetic information, including France, Sweden, and Austria. While restricting insurer use of genetic information may alleviate consumers’ concerns regarding privacy and discrimination, it also raises new concerns. Without access, at a minimum, to genetic information that affects the accuracy of underwriting, insurers may be forced to raise premiums to cover the “known unknown,” which would harm a far larger portion of the population than granting blanket access. Thus, insurers and consumers must find a middle ground — one that balances insurers’ need for relevant genetic information with consumers’ concerns regarding privacy and discrimination.

The Middle Ground

The United Kingdom provides a model for a possible middle ground for regulating insurer use of genetic information. Under the U.K. model, insurers are allowed access to genetic information, but can only use the information when it will actually help underwrite customers’ coverage. How is this different from the current status quo? Enter an independent review of the predictive value of genetic information.

For example, since 2001, insurers and the British government have agreed to prohibit the use of genetic information for all insurance policies under a specified amount (e.g., £500,000 for life insurance). However, for policies above that specified amount, insurers are allowed to use genetic test results that have been approved by a governmental body called the Genetics and Insurance Committee. (To date, only results regarding Huntington’s Disease have been approved for use, and only in life insurance applications).

Ultimately, the middle-ground model would provide insurers with the information needed to accurately underwrite customers’ coverage and, at the same time, limit potential privacy violations and discrimination. While careful consideration will need to be given to the standards for determining whether to approve the use of genetic information, the U.K. model presents a strong path forward for building a trusting relationship between insurers and consumers.

— Connect with ThinkAdvisor Life/Health on Facebook and Twitter

Matthew Bergs (Photo: Prince)

Matthew Bergs is a JD/MHA student at the University of Iowa.

Anya Prince (Photo: Prince)

Anya Prince is an associate professor at the University of Iowa College of Law. 

Anya Prince will address this topic during her keynote presentation at this year’s Global Insurance Symposium, and an in-depth analysis of these arguments is forthcoming in the Nebraska Law Review. A draft copy of the paper is available here.


© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.